Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients

to assess the efficacy of inhaled furosemide in mustard gas exposed patients with acute respiratory failure

Completed

Looking for future studies?

Key information

Conditions

Bronchiolitis Bronchial Diseases Bronchitis Dyspnea Infections Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Respiration Disorders Respiratory Aspiration Respiratory Tract Diseases Respiratory Tract Infections Signs and Symptoms Signs and Symptoms, Respiratory

Age range

32 year–83 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 3

Primary location

RCCI

Tehran, Tehran Province, Iran

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with a history of exposure to sulfur mustard with a complaint of dyspnea

Exclusion criteria

A contraindication for furosemide use;
An accompanying disease in which other drugs effective for dyspnea were used

Treatment and study plan

Furosemide

Drug

Primary outcomes

effect of furosemid inhalation on dyspnea

Sponsors and collaborators

Lead sponsor

Baqiyatallah Medical Sciences University

Other

Registry information

Official study title

Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients: a Double-Blind Randomized Study

Important dates

First posted: Aug 8, 2007
Registry last updated: Aug 8, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed